Pleural cytokines MIF and MIP-3α as novel biomarkers for complicated parapneumonic effusions and empyema

Chia-Yu Yang1,2,3, Yu-Hsuan Kuo1,4, Min Chen1,4, Chih-Liang Wang5,6, Li-Jane Shih7, Yu-Ching Liu5, Pei-Chun Hsueh4, Yi-Hsuan Lai4, Chi-Ming Chu8, Chih-Ching Wu2,3,9 & Kuo-An Wu10,11

Patients with complicated parapneumonic effusion (CPPE)/empyema have high morbidity and mortality, particularly when adequate management is delayed. We aimed to investigate novel dysregulated cytokines that can be used as biomarkers for infectious pleural effusions, especially for CPPE/empyema. Expression of 40 cytokines in parapneumonic effusions (PPE) was screened in the discovery phase, involving 63 patients, using a multiplex immunobead-based assay. Six cytokines were subsequently validated by enzyme-linked immunosorbent assays (ELISAs). We then used ELISA to further evaluate the diagnostic values and cutoff values of these cytokines as potential biomarkers in an expanded group that included 200 patients with uncomplicated parapneumonic effusion (UPPE), CPPE, empyema, transudates, other exudates, and malignant pleural effusion (MPE). The pleural levels of four cytokines (MIF, MIP-3α, IL-1β, ENA-78) were highest and significantly increased in CPPE/empyema compared with those in other etiologies. According to receiver operating characteristic curve analysis, the four cytokines (MIF, MIP-3α, IL-1β, and ENA-78) had areas under the curve (AUCs) greater than 0.710 for discriminating parapneumonic pleural effusion from noninfectious pleural effusions. In a comparison of nonpurulent CPPE with UPPE, logistic regression analysis revealed that pleural fluid MIF ≥ 12 ng/ml and MIP-3α ≥ 4.3 ng/ml had the best diagnostic value; MIF also displayed the highest odds ratio of 663 for nonpurulent CPPE, with 97.5% specificity, 94.44% sensitivity, and an AUC of 0.950. In conclusion, our results show that elevated MIF and MIP-3α may be used as novel biomarkers for PPE diagnosis, particularly in patients with CPPE/empyema; the findings indicate that dysregulated cytokine expression may provide clues about the pathogenesis of pleural infection.

Pleural effusion results from the accumulation of excess fluid in the pleural cavity; it can be classified as transudate or exudate based on clinical characterization1,2. The most common causes of exudates are pneumonia, lung abscess, and malignancy3. Approximately 20–40% of patients who are hospitalized for pneumonia develop parapneumonic effusion (PPE)4. PPE is the fluid that accompanies acute bacterial pneumonia or other infections of the lung parenchyma; it can be classified into three stages based on disease progression and pathophysiology: uncomplicated PPE (UPPE), complicated PPE (CPPE), and thoracic empyema5,6. The progression of PPEs to CPPE/empyema is associated with poor clinical outcome and increased mortality5,7. Most patients with UPPE
The pleural levels of some cytokines in patients with different etiologies have been reported previously, and some of the cytokines that show elevated levels in pleural effusions have been proposed as biomarkers for differential diagnosis of pleural effusion. Increased levels of IL-6, IL-8, and IL-1β have been reported in infectious pleural effusion compared with malignant pleural effusion, particularly when adequate management is delayed. Additionally, the criteria for clinical diagnosis of CPPE based on pleural fluid are a lactate dehydrogenase (LDH) level above 1000 U/l, a glucose level below 60 mg/dl, or a pH below 7.20; empyema refers to a condition in which there is pus in the pleural space.

Inflammation of the pleural results in increased pleural fluid accumulation and neutrophil infiltration of the pleural cavity. This pleural fluid contains various inflammatory mediators, cytokines, and metabolites. Cytokines are secreted proteins that are involved in many inflammatory responses and regulate the migration of immune cells in response to various stimuli. They bind to specific receptors on their target cells, leading to activation of the target cells and amplification of immune responses.

The levels of some cytokines in patients with different etiologies have been reported previously, and some of the cytokines that show elevated levels in pleural effusions have been proposed as biomarkers for differential diagnosis of pleural effusion. Increased levels of IL-6, IL-8, and IL-1β have been reported in infectious pleural effusion compared with malignant pleural effusion and transudates. Among the PPEs, IL-8 and IL-1β levels were found to be much higher in CPPE than in UPPE. Porcel et al. reported that TNF-α in pleural fluid is a marker of CPPE. However, large-scale screening of cytokines in individual patients with pleural effusion is still lacking. In the present study, we aimed to identify novel dysregulated cytokines to serve as biomarkers for infectious pleural effusion, particularly patients with CPPE/empyema. To lower down the sample usage, forty cytokines in parapneumonic pleural effusions were quickly screened using a multiplex immunobead-based system. The potential dysregulated cytokines were identified.

### Results

Profile of 40 cytokines in pleural effusions from PPE patients. The patients' demographic data and the pleural levels of the biochemical parameters are shown in Table 1. In the first cohort, we screened the pleural levels of 40 cytokines in 63 patients with PPE (empyema: 20 patients; nonpurulent CPPE: 13 patients; UPPE: 30 patients) using a Bio-Plex Pro Human Chemokine multiplex immunoassay. The 40 candidate proteins (10 cytokines, 27 chemokines, 2 growth factors, and 1 other) were selected for screening because these proteins have been reported to regulate inflammation and immune cell function/migration in gene ontological analyses (Supplementary Table S1). Among the 40 cytokines we screened as the following strategy because of the limited samples (Table 2): (1) the fold changes of fluorescence intensities were upper 1.3 and lower 0.76 between CPPE and UPPE, (2) ten cytokines (ENA-78, IL-1β, Groβ, IL-8, MIP-3α, MIF, fractalkine, MCP3, MIP-1α, and Groα) were increased, (3) two cytokines (CTACK and SDF1) were decreased, (4) twelve cytokines were selected and resolve with appropriate antibiotic therapy, and drainage is generally not necessary. In most cases of CPPE/empyema, patients require pleural drainage with or without fibrinolytics or thoracic surgery. In addition, CPPE/empyema also has a poorer prognosis than UPPE, particularly when adequate management is delayed. Traditionally, the criteria for clinical diagnosis of CPPE based on pleural fluid are a lactate dehydrogenase (LDH) level above 1000 U/l, a glucose level below 60 mg/dl, or a pH below 7.20; empyema refers to a condition in which there is pus in the pleural space.

### Table 1. Clinical characteristics of the patients in this study. *Data are presented as the mean ± SEM. NA not available, UPPE uncomplicated parapneumonic effusion, CPPE nonpurulent complicated parapneumonic effusion, MPE malignant pleural effusion. The p value on two-tailed Student's t test indicates the difference between CPPE and UPPE or the empyema and CPPE. Protein, glucose, and LDH data are missing for two patients with MPE.

| Characteristics | Empyema | CPPE | UPPE | p valueb | p valuec |
|----------------|---------|------|------|----------|----------|
| Discovery phase for multiplex immunobead-based assay |
| Patients | 20 | 13 | 30 | - | - |
| Male (%) | 17 (85.0%) | 11 (84.6%) | 26 (86.7%) | - | - |
| Age (years) | 67.80 ± 4.07 | 65.15 ± 4.55 | 67.33 ± 3.46 | 0.863 | 0.758 |
| Protein (g/dl) | 3.85 ± 0.32 | 4.39 ± 0.23 | 3.64 ± 0.16 | 0.023 | 0.573 |
| Glucose (mg/dl) | 45.72 ± 12.46 | 41.05 ± 14.02 | 158.22 ± 14.98 | <0.001 | 0.235 |
| LDH (U/l) | 8066 ± 2751 | 2267 ± 672 | 425 ± 55 | <0.001 | 0.013 |
| pH | 6.89 ± 0.08 | 7.19 ± 0.03 | 7.43 ± 0.10 | <0.001 | 0.002 |
| Characteristics | Empyema | CPPE | UPPE | Other exudates | Transudates | MPE | p valueb | p valuec |
| Six types of pleural effusion for ELISAs |
| Patients | 22 | 18 | 40 | 31 | 40 | 49 | - | - |
| Male (%) | 19 (86.3%) | 15 (83.3%) | 31 (77.5%) | 21 (67.7%) | 25 (62.5%) | 24 (48.9%) | - | - |
| Age (years) | 67.82 ± 3.95 | 60.22 ± 4.11 | 68.18 ± 3.14 | 76.09 ± 3.22 | 74.37 ± 2.65 | 67.16 ± 2.54 | 0.143 | 0.17 |
| Protein (g/dl) | 3.90 ± 0.28 | 4.62 ± 0.20 | 3.59 ± 0.15 | 3.66 ± 0.21 | 1.81 ± 0.10 | 4.02 ± 0.17 | <0.001 | 0.075 |
| Glucose (mg/dl) | 38.68 ± 10.58 | 49.26 ± 12.64 | 158.83 ± 11.67 | 140.64 ± 9.70 | 158.98 ± 7.97 | 123.28 ± 7.42 | <0.001 | 0.178 |
| LDH (U/l) | 6126 ± 1926 | 1451 ± 297 | 406 ± 48 | 186 ± 20 | 83 ± 4 | 460 ± 50 | <0.001 | 0.005 |
| pH | 6.95 ± 0.07 | 7.19 ± 0.03 | 7.44 ± 0.02 | 7.44 ± 0.01 | 7.47 ± 0.01 | NA | <0.001 | 0.019 |
examined the statistical significance between CPPE and UPPE using Mann–Whitney U test, (5) Bonferroni-adjusted p values < 0.05/24 (12 cytokines and 2 comparisons) = 0.0021 indicated significance. The results showed that 9 up-regulated cytokines and 1 down-regulated cytokine showed statistical significantly difference (Table 2).

**Validation of pleural cytokine levels in six types of pleural effusions.** Because of a lack of standard proteins in this phase, only the relative abundance of the cytokines in each sample was assessed, as based on the fluorescence intensity acquired in the multiplex immunoassay. To validate the results in the multiplex immunoassay, the 6 cytokines (MIF, MIP-3α, IL-1β, ENA78, Groα, and Groβ) were further detected with the same PPE samples using sandwich ELISAs in which standard proteins were used to determine the absolute concentrations of the cytokines (Table 3). IL-1β has been reported to increase in CPPE/empyema, the pleural level of IL-1β was determined as a control16. However, because of an insufficient volume for 16 samples, only 47 samples (17 empyema, 8 CPPE, and 22 UPPE) were available and used to perform the ELISAs. The correlation of the 6 cytokines between the multiplex immunoassay and the sandwich ELISAs is shown in Supplementary Fig. S1. The cytokine levels of these proteins in this phase, only the relative abundance of the cytokines in each sample was assessed, as based on the fluorescence intensity measured in a multiplex immunoassay.

### Table 2. Cytokine profiling in the discovery phase with the multiplex immunobead-based assay. 

| Cytokine* | Empyema (n = 20) | CPPE (n = 13) | UPPE (n = 30) | CPPE vs UPPE | Empyema vs CPPE |
|-----------|-----------------|---------------|---------------|--------------|----------------|
|           | Mean            | SEM           | Mean          | SEM          | Mean           | SEM          | Fold change | p value<sup>a</sup> | Fold change | p value<sup>a</sup> |
| **Upregulated** |                 |               |               |              |                |               |             |                   |             |                   |
|ENA78      | 960.3           | 389.45        | 311.23        | 169          | 15.17          | 10.8         | 20.52       | <0.001*        | 3.09         | 0.11             |
|IL-1β      | 4618.85         | 1098.71       | 1575.31       | 661.93       | 109.72         | 28.02        | 14.36       | <0.001*        | 2.93         | 0.03             |
|Groβ       | 644.35          | 507.02        | 29.54         | 11.63        | 3.65           | 0.94         | 8.09        | <0.001*        | 21.81        | 0.11             |
|IL-8       | 17,274.98       | 1929.63       | 11,784.88     | 2346.18      | 2084.88        | 734.5        | 14.88       | <0.001*        | 1.5          | 0.02             |
|MIP-3α     | 8710.53         | 1400.22       | 9136.23       | 9133.32      | 1648.75        | 466.3        | 10.82       | 0.002*         | 0.95         | 1.00             |
|MIP        | 7898.83         | 1281.88       | 5171.53       | 1405.81      | 944.45         | 406.91       | 5.78        | <0.001*        | 1.53         | 0.11             |
|Fractalkine| 1483.75         | 224.32        | 1512.99       | 311.15       | 286.28         | 68.39        | 5.28        | <0.001*        | 0.98         | 0.84             |
|MCP3       | 57.1            | 22.33         | 24.42         | 4.07         | 7.5            | 1.9          | 3.26        | <0.001*        | 2.34         | 0.57             |
|MIP-1α     | 2309.93         | 835.01        | 447.96        | 259.64       | 159.68         | 57.75        | 5.28        | 0.001*         | 5.16         | 0.02             |
|Groα       | 1038.58         | 791.26        | 118           | 31.68        | 84.9           | 49.86        | 1.39        | 0.002*         | 8.8          | 0.25             |
|**Downregulated** |             |               |               |              |                |               |             |                   |             |                   |
|CTACK      | 145.55          | 42            | 206           | 77.19        | 379.48         | 31.09        | 0.54        | <0.001*        | 0.71         | 0.194            |
|SDF1       | 336.13          | 151.88        | 454.27        | 120.41       | 902.57         | 75.12        | 0.5         | 0.003          | 0.74         | 0.043            |

*Data are presented as the fluorescence intensity measured in a multiplex immunobead-based assay. CPPE uncomplicated parapneumonic effusion, CPPE nonpurulent complicated parapneumonic effusion. Statistical analysis was done using Mann–Whitney U test for comparing the difference between CPPE and UPPE or Empyema and CPPE. Bonferroni-adjusted p-values < 0.05/24 (12 cytokines and 2 comparisons) = 0.0021 indicate significance.

Diagnostic values of these cytokines for distinguishing PPE from noninfectious PE. We then characterized the diagnostic value of these markers for distinguishing PPE (empyema, CPPE and UPPE) from noninfectious PE (other exudates, transudates, and MPE). The true positive rate (sensitivity) was plotted against the false positive rate (100%-specificity), and the area under the curve (AUC) was reported with a 95% confi-
Among the potential markers, MIF and MIP-3α had AUCs higher than 0.950 for distinguishing CPPE from UPPE (Table 6). Furthermore, MIP-3α had an odds ratio of 312, a specificity of 97.50%, and a sensitivity of 94.44% for distinguishing CPPE from UPPE (Table 6). The Spearman correlations among the pleural fluid levels of the six proteins and clinical parameters (glucose, LDH, and pH) in all PPE patients were calculated. The levels of the six proteins in pleural effusions showed a statistically significant positive correlation (p < 0.05; Supplementary Table S2). In conclusion, our results identify elevated MIF and MIP-3α as novel biomarkers for PPE diagnosis, particularly in patients with CPPE/empyema.

Diagnostic values of these cytokines for distinguishing CPPE from UPPE. CPPE/empyema generally has a poorer prognosis than other types of effusion, particularly when immediate medical management is delayed. To determine the efficacies of the six tested cytokines as potential markers for distinguishing nonpurulent CPPE from UPPE, logistic regression and receiver operating characteristic curve analysis were performed. Among the potential markers, MIF and MIP-3α had AUCs higher than 0.950 for distinguishing CPPE from UPPE (Table 6, Supplementary Fig. S2). Univariate logistic regression analysis demonstrated a strong association between MIF levels > 12 ng/ml and CPPE, with a high odds ratio of 663, a specificity of 97.50%, and a sensitivity of 94.44% for distinguishing CPPE from UPPE (Table 6). Furthermore, MIP-3α had an odds ratio of 312, a specificity of 95.12%, and a sensitivity of 94.11% for distinguishing CPPE from UPPE (Table 6). The diagnostic values of these cytokines for distinguishing CPPE from UPPE indicated significant positive correlation (p < 0.05; Supplementary Table S2). In conclusion, our results identify elevated MIF and MIP-3α as novel biomarkers for PPE diagnosis, particularly in patients with CPPE/empyema.

Discussion
In the discovery phase of this study, we conducted comprehensive cytokine screening of pleural fluid specimens from PPE patients using a multiplex immunoassay. Among the 40 screened cytokines, we identified two, IL-1β and IL-8, that were present at elevated levels and have previously been reported to increase in CPPE/empyema compared to UPPE.3,4. We further identified seven additional cytokines (MIF, MIP-3α, ENA-78, Groβ, Groα, MCP3, and fractalkine) that have not been reported to increase significantly in CPPE/empyema compared to UPPE. The pleural levels of CTACK have not been reported to decrease significantly in CPPE/empyema compared to UPPE. Therefore, the multiplex immunobead-based assay not only assisted in confirming the reported changes in cytokine levels that occur in PPE but also served as a tool for the discovery of novel dysregulated cytokines in PPE.

The possibility that increased pleural levels of MIF and MIP-3α may serve as biomarkers for distinguishing PPE, especially CPPE/empyema, from noninfectious PE was first explored in this study. MIF is an important regulator of protective responses to intracellular pathogens17,18; it is also linked to the pathogenesis of several inflammatory disorders19–22. High concentrations of MIF have been found in the plasma of patients with severe sepsis21–23. MIF is increased in the blood and bronchoalveolar lavage of patients with acute respiratory distress syndrome and is associated with disease outcome24,25. However, pleural levels of MIF have never been reported in PPE. In patients with parapneumonic effusion, pleural MIF may be released by macrophages, lymphocytes,

Table 3. The concentration of six cytokines in PPE patients using ELISA. *Data are presented as mean, median, and 25th–75th percentile (pg/ml). UPPE: uncomplicated parapneumonic effusion; CPPE: nonpurulent complicated parapneumonic effusion. Statistical analysis between CPPE and UPPE was done using Mann–Whitney U test. Bonferroni-adjusted p values < 0.05/12 (6 cytokines and 2 comparison) = 0.004 indicate significance.
and pulmonary epithelial cells in response to microbial stimuli, and MIF may contribute to the chemoattraction of neutrophils to the pleural cavity and enhance the production of other cytokines in PPE. Recently, Lang et al. reported that MIF may participate in the activation of the NLRP3 inflammasome. IL-1β is a proinflammatory cytokine in the toll-like receptor signaling and NLRP3 inflammasome pathways, which are crucial for host defense responses to infection. IL-1β levels were also significantly increased in PPE, especially in CPPE/empyema, and had an AUC of 0.847 for identifying nonpurulent CPPE from UPPE in our cohort; this finding is consistent with a previous report. The roles of MIF and NLRP3 inflammasome-induced IL-1β in PPE may need further investigation.

In this report, we first identified other two chemokines, Groα/CXCL1 and Groβ/CXCL2, that are also elevated in PPE, especially in CPPE/empyema, but these differences did not reach statistical significance. Paudel et al. reported that Groα/CXCL1 is a central player in host defense, granulopoiesis, and mobilization of neutrophils during bacterial infections.
pneumonia-induced sepsis in a murine model. Filippo et al. also reported that Groα/CXCL1 and Groβ/CXCL2 control neutrophil recruitment in a murine model. The pleural levels of Groa/CXCL1 and Groβ/CXCL2 in pneumonia patients have not been investigated previously; the role of these two cytokines may need further study. MIP-3α/CCL20 is involved in the chemoattraction of immature dendritic cells and effector/memory T- and B-cells to skin and mucosal surfaces. It had been reported that patients with multiple sclerosis or ischemic heart disease have higher circulating levels of chemokine MIP-3α. MIP-3α is upregulated in the cerebrospinal fluid (CSF) of patients with pneumococcal meningitis. A higher level of MIP-3α in PPE than in MPE was previously reported, but that report did not include patients with other types of pleural effusion. We further identified that the pleural level of MIP-3α was higher in PPE, especially in CPPE/empyema, than in other types of pleural effusion including UPPE, transudates, and other exudates. ENA78 has been reported to regulate neutrophil homeostasis and recruitment. It has been reported that compared with noninfectious pleural effusion (19 with malignant pleural effusion, 21 with tuberculous pleural

| Cytokine | AUC (95% CI) | Cutoff | Specificity (%) | Sensitivity (%) | PPV (%) | NPV (%) | Odds Ratio (95% CI) |
|----------|--------------|--------|----------------|----------------|---------|---------|-------------------|
| MIP (pg/ml) | 0.710 (0.630–0.789) | > 4800 | 73.33 | 61.25 | 60.49 | 73.95 |
| MIP-3α (pg/ml) | 0.828 (0.762–0.895) | > 450 | 95.83 | 67.50 | 91.52 | 81.56 |
| IL-1β (pg/ml) | 0.820 (0.753–0.888) | > 40 | 99.17 | 61.25 | 98.00 | 79.47 |
| ENA78 (pg/ml) | 0.771 (0.699–0.843) | > 150 | 93.33 | 62.50 | 86.20 | 78.87 |
| Groβ (pg/ml) | 0.670 (0.588–0.752) | > 30 | 77.50 | 51.25 | 60.29 | 70.46 |
| Groα (pg/ml) | 0.528 (0.441–0.615) | – | – | – | – | – |

**Table 5.** Diagnostic accuracy of six cytokines for distinguishing between PPE and noninfectious PE. Parapneumonic effusion (PPE, refers to UPPE, CPPE, and empyema) and noninfectious PE (refers to other exudates, transudates, and MPE) in this study. **PPV** positive predictive value, **NPV** negative predictive value, **AUC** area under ROC curve.

| Cytokine | AUC (95% CI) | Cutoff | Specificity (%) | Sensitivity (%) | PPV (%) | NPV (%) | Odds Ratio (95% CI) |
|----------|--------------|--------|----------------|----------------|---------|---------|-------------------|
| MIP (pg/ml) | 0.950 (0.863–1.000) | > 12,000 | 97.50 | 94.44 | 94.44 | 97.50 | 663.00 (30.13–11,231.83) |
| MIP-3α (pg/ml) | 0.953 (0.891–1.000) | > 4300 | 95.12 | 94.11 | 88.88 | 97.50 | 312.00 (26.39–2688.51) |
| IL-1β (pg/ml) | 0.847 (0.730–0.964) | > 145 | 86.04 | 80.00 | 66.66 | 92.50 | 24.66 (5.33–114.05) |
| ENA78 (pg/ml) | 0.932 (0.870–0.994) | > 400 | 82.50 | 61.11 | 61.11 | 82.50 | 7.40 (2.12–25.86) |
| Groβ (pg/ml) | 0.840 (0.727–0.954) | > 30 | 83.33 | 68.75 | 87.50 | 87.50 | 11.00 (2.90–41.70) |
| Groα (pg/ml) | 0.671 (0.509–0.833) | – | – | – | – | – | – |

**Table 6.** Diagnostic accuracy of six cytokines for distinguishing between CPPE and UPPE. **PPV** positive predictive values, **NPV** negative predictive values, **AUC** area under ROC curve.
effusion, 17 with transudates), the pleural levels of ENA78 were significantly increased in infectious pleural effusion (n = 18)\(^3\). In our study, we further classified infectious pleural effusions as empyema, CPPE, or UPPE; ENA78 levels were significantly increased in CPPE/empyema compared with UPPE.

Among the patients with PPE, the mechanism of progression from UPPE to CPPE/empyema is unclear. Findings from previous reports and our study of PPE suggest that elevated pleural levels of various inflammatory cytokines, including IL-6, IL-8, TNF-\(\alpha\), MIF, MIP3\(\alpha\), IL-1\(\beta\), ENA78, Groa, and Gro\(\beta\), may contribute to the development of pleural inflammation. The proinflammatory cytokines (IL-6, IL-8, TNF-\(\alpha\)) initiate the immune activation cascade, leading to stimulation of immune cells and epithelial cells and the production of other cytokines. Elevated levels of MIF, ENA78, Groa, and Gro\(\beta\) may enhance the influx of neutrophils into the pleural space. In addition, MIF induces excessive macrophage and neutrophil activation, leading to IL-1\(\beta\) production. At the end stage, toxic neutrophil granule proteins are released, and fibroblast proliferation and fibrin deposition result in pus formation. Limited by our sample magnitude, Groa and Gro\(\beta\) levels displayed an increasing trend in CPPE/empyema compared to other conditions, though a significant difference was not reached. Nevertheless, levels of Groa and Gro\(\beta\) in pleural effusions are an important issue, and further characterization is needed.

In addition to the above, we demonstrated that two cytokines, CTACK and SDF-1, are downregulated in CPPE/empyema compared to UPPE and potentially identified a previously unknown involvement of CTACK and SDF-1 in pneumonia or pleuritis. CTACK, also known as chemokine ligand 27 (CCL27), was reported to attract CPPE/empyema compared to UPPE and potentially identified a previously unknown involvement of CTACK and Gro\(\alpha\) and Gro\(\beta\) in pleural effusions as an important issue, and further characterization is needed.

Methods

Study design and population. In this prospective study, a total of 216 patients were enrolled from June 2014 to June 2018. The participants in the first cohort were enrolled at Taoyuan Armed Forces General Hospital, Taiwan. The participants in the ELISA platform were enrolled at Taoyuan Armed Forces General Hospital and Chang Gung Memorial Hospital, Taiwan. The study was approved by the Institutional Review Boards of the Tri-Service General Hospital (TSGH) and Chang Gung Memorial Hospital (CGMH), Taiwan (approval number: 105-2109C, 201700601B0, TY102-06). Patients with PPE, other exudates, and transudates were all enrolled in Taoyuan Armed Forces General Hospital. MPE is an advanced disease usually requiring surgical removal of cancer. Chang Gung Memorial Hospital Taiwan is a medical center at Taoyuan City responsible for cancer patients transferred from the Taoyuan Armed Forces General Hospital. Therefore, the samples of MPE were collected at Chang Gung Memorial Hospital. All experiments were performed in accordance with the guidelines and regulations set forth by the Institutional Review Boards of TSGH and CGMH. Prior to sample collection, written informed consent to participation in the study was obtained from all patients. All adult patients with pleural effusion who underwent diagnostic thoracentesis were considered for enrollment in this study by the attending physicians. If a patient underwent more than one thoracentesis during the hospitalization period, the samples obtained at the first tap were considered. The patients were divided into six groups according to the cause of the pleural effusion: transudates (40 patients), malignant pleural effusions (MPE; 49 patients), UPPE (48 patients), nonpurulent CPPE (23 patients), empyema (25 patients) and other exudates (31 patients). Transudates were effusions secondary to heart failure (22 patients), hypoalbuminemia (13 patients), liver cirrhosis (3 patients), or renal failure (2 patients). The primary tumors in malignant effusions were lung (40 patients), breast (1 patient), unknown (7 patients), and lymphoma (1 patient). Among the other exudates, there were 9 idiopathic, 7 trapped lungs, 4 intrabdominal infection, 2 postcardiac injury syndrome, 2 post-heart surgery, 2 pulmonary embolism, 1 hemothorax, 1 uremic pleurisy, 1 Sjögren’s syndrome, 1 aortic dissection, and 1 chylothorax. The discovery phase included 63 patients (UPPE: 30 patients; nonpurulent CPPE: 13 patients; empyema: 20 patients) and was based on a multiplex immunobead-based assay. The validation phase included 200 patients (transudates: 40 patients; other exudates: 31 patients; MPE: 49 patients; UPPE: 40 patients (n = 22 from the discovery phase and 18 new patients); nonpurulent CPPE: 18 patients (n = 8 from the discovery phase and 10 new patients); empyema: 22 patients (n = 17 from the discovery phase and 5 new patients) and was based on ELISA assays.
Diagnostic criteria. Pleural effusions are classically divided into transudates and exudates based on Light's criteria. A pleural effusion is categorized as MPE if malignant cells are demonstrated in pleural fluid or pleural biopsy. PPE refers to a pleural fluid collection resulting from bacterial pneumonia, lung abscess, or bronchiectasis and is further classified as UPPE, nonpurulent CPPE, or empyema. Nonpurulent CPPE is defined as the presence of PPE with one of the following additional criteria: (1) pH < 7.2, (2) glucose < 60 mg/dl, (3) LDH > 1000 U/l, or (4) bacteria found on Gram's stain or culture. Frank pus is termed empyema. Otherwise, UPPE is considered to exist when the patient's exudative pleural fluid meets only one or none of the above criteria. After collection, the effusions were centrifuged at 3000 rcf for 10 min. Acellular supernatants were collected and stored at −80 °C until use in the experiments.

Multiplex analysis of 40 cytokines and chemokines. The pleural levels of cytokines and chemokines were determined through the use of Bio-Plex Pro™ Assays (Bio-Rad Laboratories, CA, USA) in the multiplex suspension array system. The Bio-Plex Pro Human Chemokine Assay (171-AK99MR2) measures 40 targets: B cell-attracting chemokine 1 (BCA-1), cutaneous T-cell-attracting chemokine (CTACK), epithelial-derived neutrophil-activating peptide 78 (ENA-78), eosinophil chemotactic protein 1 (eotaxin-1), eosinophil chemotactic protein 2 (eotaxin-2), eosinophil chemotactic protein 3 (eotaxin-3), fractalkine, granulocyte chemotactic protein 2 (GCP-2), growth-regulated oncogene-α (Groα), growth-regulated oncogene-β (Groβ), granulocyte–macrophage colony-stimulating factor (GM-CSF), interferon γ (IFN-γ), IFN-γ-induced protein 10 (IP-10), interferon-inducible T-cell alpha chemoattractant (I-TAC), I-309, macrophage migration inhibitory factor (MIF), monocyte chemoattractant protein (MCP)-1, MCP-2, MCP-3, MCP-4, macrophage-derived chemokine (MDC), monokine induced by IFN-γ (MIG), macrophage inflammatory protein (MIP)-1α, MIP-3α, MIP-3β, MIP-1β, myeloid progenitor inhibitory factor 1 (MPIF-1), interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, stromal cell-derived factor 1 (SDF1), small inducible cytokine B16 (SCYB16), thymus-expressed chemokine (TECK), thymus- and activation-regulated chemokine (TARC), and tumor necrosis factor (TNF)-α. The assays were performed in 96-well microplates according to the protocol provided by Bio-Rad Laboratories.

Enzyme-linked immunosorbent assay. Commercial sandwich ELISA kits (R&D Systems, MN, USA) were used to measure the levels of macrophage migration inhibitory factor (MIF), interleukin 1β (IL-1β), epithelial neutrophil-activating protein 78 (ENA-78), macrophage inflammatory protein-3α (MIP-3α), growth-regulated oncogene β (Groβ), and growth-regulated oncogene a (Groα) in pleural effusions. The assays were performed according to the manufacturer's guidelines.

Statistical analysis. In the multiplex immunobead-based assay, among the 40 cytokines we screened as the following strategy because of the limited samples (Table 2), (1) the fold changes of fluorescence intensities were upper 1.3 and lower 0.76 between CPPE and UPPE, (2) ten cytokines (ENA-78, IL-1β, Groβ, IL-8, MIP-3α, MIF, fractalkine, MCP3, MIP-1α, and Groα) were increased, (3) two cytokines (CTACK and SDF1) were decreased, (4) twelve cytokines were selected and examined the statistical significance between CPPE and UPPE using Mann–Whitney U test. 5. Bonferroni-adjusted p values <0.05/24 (12 cytokines and 2 comparisons) = 0.0021 indicated significance.

The pleural levels of target proteins in ELISAs were showed as mean, median, and 25th–75th percentiles. Statistical analysis was done using the post hoc Turkey test for comparison the six cytokines among six different subgroups of patients. Bonferroni-adjusted p values were calculated as a error 0.05 divided by numbers of cytokines and comparisons on each table.

ROC curves were generated by plotting sensitivity versus 1-specificity. The area under the curve (AUC) was reported with 95% confidence intervals as an estimate of diagnostic usefulness. The optimal cutoff value of each cytokine level was determined as the sum of its maximum sensitivity and specificity. Univariable logistic regression was performed to analyze the association between pleural biomarkers and the presence of CPPE. Unadjusted ORs were calculated as an estimate of risk. Spearman correlations were calculated to measure the associations among the candidate protein markers for PPE patients. All statistical tests were performed using SPSS software version 20 (SPSS Inc., Chicago, IL, USA).

Received: 9 April 2020; Accepted: 2 December 2020
Published online: 19 January 2021

References
1. Porcel, J. M., Esquerda, A., Vives, M. & Bielsa, S. Etiology of pleural effusions: Analysis of more than 3,000 consecutive thoracenteses. Arch. Bronconeumol. 50, 161–165 (2014).
2. Light, R. W. Pleural effusions. Med. Clin. N. Am. 95, 1055–1070 (2011).
3. Na, M. J. Diagnostic tools of pleural effusion. Tuberc. Respir. Dis. (Seoul) 76, 199–210 (2014).
4. Light, R. W. Parapneumonic effusions and empyema. Proc. Am. Thorac. Soc. 3, 75–80 (2006).
5. Light, R. W., Girard, W. M., Jenkinson, S. G. & George, R. B. Parapneumonic effusions. Am. J. Med. 69, 507–512 (1980).
6. McCauley, L. & Dean, N. Pneumonia and empyema: Causal, casual or unknown. J. Thorac. Dis. 7, 992–998 (2015).
7. Davies, H. E., Davies, R. J., Davies, C. W. & Group, B. T. S. P. D. G. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 65, 41–53 (2010).
8. Colice, G. L. et al. Medical and surgical treatment of parapneumonic effusions: An evidence-based guideline. Chest 118, 1158–1171 (2000).
9. Falguera, M. et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. Eur. Respir. J. 38, 1173–1179 (2011).
10. Corcoran, J. P. et al. Pleural infection: Past, present, and future directions. Lancet Respir. Med. 3, 563–577 (2015).
11. Wu, K. A. et al. Proteome profiling reveals novel biomarkers to identify complicated parapneumonic effusions. Sci. Rep. 7, 4026 (2017).
12. Porcel, J. M. Pleural fluid tests to identify complicated parapneumonic effusions. Curr. Opin. Pulm. Med. 16, 357–361 (2010).
13. Griffith, J. W., Sokol, C. L. & Luster, A. D. Chemokines and chemokine receptors: Positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659–702 (2014).
14. San Jose, M. E. et al. Diagnostic value of proinflammatory interleukins in parapneumonic effusions. Am. J. Clin. Pathol. 133, 884–891 (2010).
15. San Jose, M. E. et al. Utility of measurement of interleukin-1β and interleukin-8 in the diagnosis of complicated parapneumonic pleural effusions. Am. J. Clin. Pathol. 142, 467–473 (2014).
16. Marchi, E. et al. Proinflammatory and antiinflammatory cytokine levels in complicated and noncomplicated parapneumonic pleural effusions. Chest 141, 183–189 (2012).
17. Calandra, T. & Roger, T. Macrophage migration inhibitory factor: A regulator of innate immunity. Nat. Rev. Immunol. 3, 791–800 (2003).
18. Das, R. et al. Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 110, E2997–3006 (2013).
19. Morand, E. F., Lecoeur, M. & Bernhagen, J. MIF: A new cytokine link between rheumatoid arthritis and atherosclerosis. Nat. Rev. Drug Discov. 5, 399–410 (2006).
20. Santos, L. L. & Morand, E. F. Macrophage migration inhibitory factor: A key cytokine in RA, SLE and atherosclerosis. Clin. Chim. Acta 399, 1–7 (2009).
21. Calandra, T. et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6, 164–170 (2000).
22. Lehmann, L. E. et al. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med. 27, 1412–1415 (2001).
23. Emonts, M. et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin. Infect. Dis. 44, 1321–1328 (2007).
24. Lai, K. N. et al. Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J. Pathol. 199, 496–508 (2003).
25. Gao, L. et al. Macrophage migration inhibitory factor in acute lung injury: Expression, biomarker, and associations. Transl. Res. 150, 18–29 (2007).
26. Lang, T. et al. Macrophage migration inhibitory factor is required for NLRP3 inflammasome activation. Nat. Commun. 9, 2223 (2018).
27. Paudel, S. et al. CXCL1 regulates neutrophil homeostasis in pneumonia-derived sepsis caused by Streptococcus pneumoniae serotype 3. Blood 133, 1335–1345 (2019).
28. De Filippo, K. et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 121, 4930–4937 (2013).
29. Schutyser, E., Struyf, S. & Van Damme, J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14, 409–426 (2003).
30. Ijaz, S. et al. Higher circulating levels of chemokine CCL20 in patients with multiple sclerosis: Evaluation of the influences of chemokine gene polymorphism, gender, treatment and disease pattern. J. Mol. Neurosci. 53, 500–505 (2014).
31. Saia, A. et al. Higher circulating levels of chemokines CXCL10, CCL20 and CCL22 in patients with ischemic heart disease. Cytokine 83, 147–157 (2016).
32. Kastenbauer, S., Angele, B., Sperer, B., Pfister, H. W. & Koedel, U. Patterns of protein expression in infectious meningitis: A cerebrospinal fluid protein array analysis. J. Neuroimmunol. 164, 134–139 (2005).
33. Yang, G. et al. Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis. Oncol. Rep. 33, 478–484 (2015).
34. Liu, G. N. et al. Epithelial neutrophil-activating peptide-78 recruits neutrophils into pleural effusion. Eur. Respir. J. 34, 184–190 (2009).
35. Honney, B. et al. CXCL7–CCL10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 8, 157–165 (2002).
36. Kakinuma, T. et al. Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. J. Allergy Clin. Immunol. 111, 592–597 (2003).
37. Isaacs, B. et al. Stromal cell-derived factor 1 mediates immune cell attraction upon urinary tract infection. Cell Rep. 20, 40–47 (2017).
38. Burgoyne, C. H. et al. Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Ann. Rheum. Dis. 67, 750–757 (2008).
39. Tsai, P. K. et al. Elevated plasma stromal-cell-derived factor-1 protein levels correlate with severity in patients with community-acquired pneumonia. Dis. Mark. 2014, 829706 (2014).

Acknowledgements
This work was supported by Grants to Kao-An Wu from Taoyuan Armed Forces General Hospital, Taiwan (AFTYGH-10739, AFTYGH-10802), Grants from the Ministry of Science and Technology (MOST) to Chia-Yu Yang (MOST 104-2321-B-182-009-MY3) and Chih-Chang Wu (MOST 108-2320-B-030-030-MY3), and Grants from Chang Gung Memorial Hospital to Chia-Yu Yang (CMRPD1G0362 and CMRPD1G0363) and Chih-Chang Wu (CLRPD190018 and BMRC77). The work was also supported by Grants to the Molecular Medicine Research Center (CLRPD1J0012), Chang Gung University from the Featured Areas Research Center Program within the Framework of Higher Education Sprout Project of the Ministry of Education of Taiwan (EMRPD1K0281).

Author contributions
C.Y.Y. contributed to the study design, data analysis, drafting, revision, and final approval of the manuscript and is accountable for all aspects of the work. C.I.W. contributed to the clinical data analysis. Y.H.K., M.C., L.I.S., Y.C.I., P.C.H., Y.H.L., and C.C.W. contributed to the experiments and the data analysis. C.M.C. contributed to the statistical analysis of the data. K.A.W. contributed to the study design and data analysis, wrote the manuscript, gave final approval of the manuscript and is accountable for all aspects of the work. All authors have approved the final version of the work.

Competing interests
The authors declare no competing interests.
Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-81053-6.

Correspondence and requests for materials should be addressed to C.-C.W. or K.-A.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021